ALTRAZEAL LIFE SCIENCES INC — Department of Defense SBIR Phase II: DHA SBIR SEQUENTIAL PHASE II, PROPOSAL NO. H2S-0071, TITLED: "DEVELOPING AN IDEAL FIRST US
ALTRAZEAL LIFE SCIENCES INC — SBIR Phase II award from Department of Defense.
Phase II SBIR prototype / development signal
- Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- Obligated amount $1,300,000 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
- Tagged technology areas: Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.
Summary
This Phase II award provides $1.3M to develop a first-use medical agent that prevents sepsis in trauma wounds during battlefield care. The goal is to improve survival for injured service members by enabling rapid wound treatment under fire.
- Amount
- $1,300,000
- Agency
- Department of Defense · Defense Health Agency
- Program / Phase
- SBIR · Phase II
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- TX
- Period
- 2025-02-07 → 2027-06-06
Technology domains
Description
DHA SBIR SEQUENTIAL PHASE II, PROPOSAL NO. H2S-0071, TITLED: "DEVELOPING AN IDEAL FIRST USE AGENT TO PREVENT SEPSIS IN TRAUMA WOUNDS DURING CARE UNDER FIRE."